المؤلفون: Panzuto, Francesco, Partelli, Stefano, Campana, Davide, de Braud, Filippo, Spada, Francesca, Cives, Mauro, Tafuto, Salvatore, Bertuzzi, Alexia, Gelsomino, Fabio, Bergamo, Francesca, Marcucci, Stefano, Mastrangelo, Laura, Massironi, Sara, Appetecchia, Marialuisa, Filice, Angelina, Badalamenti, Giuseppe, Bartolomei, Mirco, Amoroso, Vito, Landoni, Luca, Rodriquenz, Maria Grazia, Valente, Monica, Colao, Annamaria, Isidori, Andrea, Fanciulli, Giuseppe, Bollina, Roberto, Ciola, Michele, Butturini, Giovanni, Marconcini, Riccardo, Arvat, Emanuela, Cinieri, Saverio, Berardi, Rossana, Baldari, Sergio, Riccardi, Ferdinando, Spoto, Chiara, Giuffrida, Dario, Gattuso, Domenico, Ferone, Diego, Rinzivillo, Maria, Bertani, Emilio, Versari, Annibale, Zerbi, Alessandro, Lamberti, Giuseppe, Lauricella, Eleonora, Pusceddu, Sara, Fazio, Nicola, Dell’Unto, Elisabetta, Marini, Marco, Falconi, Massimo

المساهمون: Panzuto, Francesco, Partelli, Stefano, Campana, Davide, de Braud, Filippo, Spada, Francesca, Cives, Mauro, Tafuto, Salvatore, Bertuzzi, Alexia, Gelsomino, Fabio, Bergamo, Francesca, Marcucci, Stefano, Mastrangelo, Laura, Massironi, Sara, Appetecchia, Marialuisa, Filice, Angelina, Badalamenti, Giuseppe, Bartolomei, Mirco, Amoroso, Vito, Landoni, Luca, Rodriquenz, Maria Grazia, Valente, Monica, Colao, Annamaria, Isidori, Andrea, Fanciulli, Giuseppe, Bollina, Roberto, Ciola, Michele, Butturini, Giovanni, Marconcini, Riccardo, Arvat, Emanuela, Cinieri, Saverio, Berardi, Rossana, Baldari, Sergio, Riccardi, Ferdinando, Spoto, Chiara, Giuffrida, Dario, Gattuso, Domenico, Ferone, Diego, Rinzivillo, Maria, Bertani, Emilio, Versari, Annibale, Zerbi, Alessandro, Lamberti, Giuseppe, Lauricella, Eleonora, Pusceddu, Sara, Fazio, Nicola, Dell’Unto, Elisabetta, Marini, Marco, Falconi, Massimo

مصطلحات موضوعية: neuroendocrine tumor, epidemiology, registry, management, database

الوصف: Neuroendocrine neoplasms (NENs) are rare tumors with diverse clinical behaviors. Large databases like the Surveillance, Epidemiology, and End Results (SEER) program and national NEN registries have provided significant epidemiological knowledge, but they have limitations given the recent advancements in NEN diagnostics and treatments. For instance, newer imaging techniques and therapies have revolutionized NEN management, rendering older data less representative. Additionally, crucial parameters, like the Ki67 index, are missing from many databases. Acknowledging these gaps, the Italian Association for Neuroendocrine Tumors (Itanet) initiated a national multicenter prospective database in 2019, aiming to gather data on newly-diagnosed gastroenteropancreatic neuroendocrine (GEP) NENs. This observational study, coordinated by Itanet, includes patients from 37 Italian centers. The database, which is rigorously maintained and updated, focuses on diverse parameters including age, diagnostic techniques, tumor stage, treatments, and survival metrics. As of October 2023, data from 1,600 patients have been recorded, with an anticipation of reaching 3600 by the end of 2025. This study aims at understanding the epidemiology, clinical attributes, and treatment strategies for GEP-NENs in Italy, and to introduce the Itanet database project. Once comprehensive follow-up data will be acquired, the goal will be to discern predictors of treatment outcomes and disease prognosis. The Itanet database will offer an unparalleled, updated perspective on GEP-NENs, addressing the limitations of older databases and aiding in optimizing patient care.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/38175391; firstpage:1; lastpage:6; numberofpages:6; journal:ENDOCRINE; https://hdl.handle.net/11573/1698345Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85181457689

الإتاحة: https://doi.org/10.1007/s12020-023-03649-4Test
https://hdl.handle.net/11573/1698345Test

المؤلفون: Mostaghim, Anahita, Minkove, Samuel, Aguilar Company, Juan, Ruiz, Isabel (Ruiz Camps), Eremiev-Eremiev, Simeon, Dettorre, Gino M., Fox, Laura, Tondini, Carlo, Brunet, Joan, Carmona-García, M. Carmen, Lambertini, Matteo, Bower, Mark, Newsom-Davis, Thomas, Sharkey, Rachel, Pria, Alessia dalla, Rossi, Maura, Plaja, Andrea, Salazar Soler, Ramón, Sureda, Anna, Prat Aparicio, Aleix, Michalarea, Vasiliki, Hemelrijck, Mieke Van, Sita Lumsden, Ailsa, Bertuzzi, Alexia, Rimassa, Lorenza, Rossi, Sabrina, Rizzo, Gianpiero, Pedrazzoli, Paolo, Lee, Alvin J. X., Murphy, Cian, Belessiotis, Katherine, Diamantis, Nikolaos, Mukherjee, Uma, Pommeret, Fanny, Stoclin, Annabelle, Martinez-Vila, Clara, Bruna, Riccardo, Gaidano, Gianluca, D’Avanzo, Francesca, Gennari, Alessandra, Athale, Janhavi, Eichacker, Peter, Pinato, David J., Torabi-Parizi, Parizad, Cortellini, Alessio, OnCovid study group

المصدر: Articles publicats en revistes (Ciències Clíniques)

مصطلحات موضوعية: COVID-19, Immunoteràpia, Càncer, SARS-CoV-2, Immunotheraphy, Cancer

الوصف: Objectives: To date, studies have not provided definitive answers regarding whether previous immune checkpoint inhibitor (ICI) treatment alters outcomes for cancer patients with COVID-19. Methods: The OnCovid registry (NCT04393974) was searched from February 27, 2020, to January 31, 2022, for patients who received systemic anti-cancer therapy in the 4 weeks before laboratory-confirmed COVID-19 diagnosis. Propensity-score matching using country, vaccination status, primary tumor type, sex, age, comorbidity burden, tumor stage, and remission status investigated differences in predefined clinical outcomes comparing those who had or had not received ICIs. Results: Of 3523 patients screened, 137 ICI-only and 1378 non-ICI met inclusion criteria. Before matching, ICI patients were older, male, enrolled at centers in Italy, and had histories of smoking, thoracic cancers, advanced cancer stages, and active malignancies (P ≤0.02). After matching, there were 120 ICI and 322 non-ICI patients. ICI patients had no differences (odds ratio: 95% CI) in presenting COVID-19 symptoms (0.69: 0.37-1.28), receipt of COVID-specific therapy (0.88: 0.54-1.41), 14-day (0.95: 0.56-1.61), or 28-day (0.79: 0.48-1.29) mortalities. However, ICI patients required less COVID-19-related hospitalization (0.37: 0.21-0.67) and oxygen therapy (0.51: 0.31-0.83) and developed fewer complications (0.57: 0.36-0.92). Conclusion: In this propensity-score matched analysis, previous ICI therapy did not worsen and potentially improved COVID-19 outcomes in patients with cancer.

وصف الملف: 8 p.; application/pdf

العلاقة: Reproducció del document publicat a: https://doi.org/10.1016/j.ijid.2023.11.021Test; International Journal of Infectious Diseases, 2024, vol. 139, p. 13-20; https://doi.org/10.1016/j.ijid.2023.11.021Test; http://hdl.handle.net/2445/213448Test; 746476

الإتاحة: https://doi.org/10.1016/j.ijid.2023.11.021Test
http://hdl.handle.net/2445/213448Test

المؤلفون: Vincenzi, Bruno, Cortellini, Alessio, Mazzocca, Alessandro, Orlando, Sarah, Romandini, Davide, Aguilar Company, Juan, Ruiz Camps, Isabel, Valverde Morales, Claudia, Eremiev Eremiev, Simeon, Tondini, Carlo, Brunet, Joan, Bertulli, Rossella, Provenzano, Salvatore, Bower, Mark, Generali, Daniele, Salazar, Ramon, Sureda, Anna, Prat, Aleix, Vasiliki, Michalarea, Hemelrijck, Mieke Van, Sita Lumsden, Ailsa, Bertuzzi, Alexia, Rossi, Sabrina, Jackson, Amanda, Grosso, Federica, Lee, Alvin J. X., Murphy, Cian, Belessiotis, Katherine, Mukherjee, Uma, Pommeret, Fanny, Loizidou, Angela, Gaidano, Gianluca, Dettorre, Gino M., Grisanti, Salvatore, Tucci, Marco, Fulgenzi, Claudia A. M., Gennari, Alessandra, Napolitano, Andrea, Pinato, David J.

المصدر: Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

مصطلحات موضوعية: SARS-CoV-2, Quimioteràpia, Chemotherapy

الوصف: Background: To date, limited evidence exists on the impact of COVID-19 in patients with soft tissue sarcoma (STS), nor about the impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in this specific population.Methods: We described COVID-19 morbidity and mortality among patients with STS across 'Omicron' (15 December 2021-31 January 2022), 'Pre-vaccination' (27 February 2020-30 November 2020), and 'Alpha-Delta' phase (01 December 2020-14 December 2021) using OnCovid registry participants (NCT04393974). Case fatality rate at 28 days (CFR28) and COVID-19 severity were also described according to the SARS-CoV-2 vaccination status, while the impact of the receipt of cytotoxic chemotherapy within 4 weeks prior to COVID-19 on clinical outcomes was assessed with Inverse Probability of Treatment Weighting (IPTW) models adjusted for possible confounders.Results: Out of 3820 patients, 97 patients with STS were included. The median age at COVID-19 diagnosis was 56 years (range: 18-92), with 65 patients (67%) aged < 65 years and most patients had a low comorbidity burden (65, 67.0%). The most frequent primary tumor sites were the abdomen (56.7%) and the gynecological tract (12.4%). In total, 36 (37.1%) patients were on cytotoxic chemotherapy within 4 weeks prior to COVID-19. The overall CFR28 was 25.8%, with 38% oxygen therapy requirement, 34% rate of complications, and 32.3% of hospitalizations due to COVID-19. CFR28 (29.5%, 21.4%, and 12.5%) and all indicators of COVID-19 severity demonstrated a trend toward a numerical improvement across the pandemic phases. Similarly, vaccinated patients demonstrated numerically improved CFR28 (16.7% versus 27.7%) and COVID-19 morbidity compared with unvaccinated patients. Patients who were on chemotherapy experienced comparable CFR28 (19.4% versus 26.0%, p = 0.4803), hospitalizations (50.0% versus 44.4%, p = 0.6883), complication rates (30.6% versus 34.0%, p = 0.7381), and oxygen therapy requirement (28.1% versus 40.0%, p = 0.2755) compared to ...

وصف الملف: 11 p.; application/pdf

العلاقة: Reproducció del document publicat a: https://doi.org/10.1177/17588359231225028Test; Therapeutic Advances in Medical Oncology, 2024, vol. 16; https://doi.org/10.1177/17588359231225028Test; http://hdl.handle.net/2445/207224Test

الإتاحة: https://doi.org/10.1177/17588359231225028Test
http://hdl.handle.net/2445/207224Test

المؤلفون: Valenti, Mario, Gargiulo, Luigi, Ibba, Luciano, Bertuzzi, Alexia, Manara, Sofia, Toso, Francesco, Costanzo, Antonio, Narcisi, Alessandra

المصدر: Journal of Dermatological Treatment ; volume 35, issue 1 ; ISSN 0954-6634 1471-1753

الإتاحة: https://doi.org/10.1080/09546634.2024.2319303Test

المؤلفون: Palassini, Elena, Baldi, Giacomo Giulio, Sulfaro, Sara, Barisella, Marta, Bianchi, Giuseppe, Campanacci, Domenico, Fiore, Marco, Gambarotti, Marco, Gennaro, Massimiliano, Morosi, Carlo, Navarria, Federico, Palmerini, Emanuela, Sangalli, Claudia, Sbaraglia, Marta, Trama, Annalisa, Asaftei, Sebastian, Badalamenti, Giuseppe, Bertulli, Rossella, Bertuzzi, Alexia Francesca, Biagini, Roberto, Bonadonna, Angela, Brunello, Antonella, Callegaro, Dario, Cananzi, Ferdinando, Cianchetti, Marco, Collini, Paola, Comandini, Danila, Curcio, Annalisa, D'Ambrosio, Lorenzo, De Pas, Tommaso, Dei Tos, Angelo Paolo, Ferraresi, Virginia, Ferrari, Andrea, Franchi, Alessandro, Frezza, Anna Maria, Fumagalli, Elena, Ghilli, Matteo, Greto, Daniela, Grignani, Giovanni, Guida, Michele, ibrahim, Toni, Krengli, Marco, Luksch, Roberto, Marrari, Andrea, Mastore, Marinella, Merlini, Alessandra, Milano, Giuseppe Maria, Navarria, Piera, Pantaleo, Maria Abbondanza, Parafioriti, Antonina

المصدر: Cancer Treatment Reviews ; volume 126, page 102722 ; ISSN 0305-7372

مصطلحات موضوعية: Radiology, Nuclear Medicine and imaging, Oncology, General Medicine

الإتاحة: https://doi.org/10.1016/j.ctrv.2024.102722Test
https://api.elsevier.com/content/article/PII:S0305737224000495?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0305737224000495?httpAccept=text/plainTest

المؤلفون: D'Ambrosio, Lorenzo, Fumagalli, Elena, De Pas, Tommaso Martino, Nannini, Margherita, Bertuzzi, Alexia, Carpano, Silvia, Boglione, Antonella, Buonadonna, Angela, Comandini, Danila, Gasperoni, Silvia, Vincenzi, Bruno, Brunello, Antonella, Badalamenti, Giuseppe, Maccaroni, Elena, Baldi, Giacomo Giulio, Merlini, Alessandra, Mogavero, Andrea, Ligorio, Francesca, Pennacchioli, Elisabetta, Conforti, Fabio, Manessi, Giulia, Aliberti, Sandra, Tolomeo, Francesco, Fiore, Marco, Sbaraglia, Marta, Dei Tos, Angelo Paolo, Stacchiotti, Silvia, Pantaleo, Maria Abbondanza, Gronchi, Alessandro, Grignani, Giovanni

المساهمون: D'Ambrosio, Lorenzo, Fumagalli, Elena, De Pas, Tommaso Martino, Nannini, Margherita, Bertuzzi, Alexia, Carpano, Silvia, Boglione, Antonella, Buonadonna, Angela, Comandini, Danila, Gasperoni, Silvia, Vincenzi, Bruno, Brunello, Antonella, Badalamenti, Giuseppe, Maccaroni, Elena, Baldi, Giacomo Giulio, Merlini, Alessandra, Mogavero, Andrea, Ligorio, Francesca, Pennacchioli, Elisabetta, Conforti, Fabio, Manessi, Giulia, Aliberti, Sandra, Tolomeo, Francesco, Fiore, Marco, Sbaraglia, Marta, Dei Tos, Angelo Paolo, Stacchiotti, Silvia, Pantaleo, Maria Abbondanza, Gronchi, Alessandro, Grignani, Giovanni

مصطلحات موضوعية: GIST, Follow up

الوصف: Importance: Gastrointestinal stromal tumor (GIST) follow-up is recommended by international guidelines, but data on the role of follow-up in patients with low relapse risk are missing. For these patients, the potential benefit of anticipating recurrence detection should be weighed against psychological burden and radiologic examination loads in terms of costs and radiation exposure. Objective: To evaluate the outcomes of guideline-based follow-up in low-risk GIST. Design, setting, and participants: This multi-institutional retrospective cohort study involving Italian Sarcoma Group reference institutions evaluated patients with GIST who underwent surgery between January 2001 and June 2019. Median follow-up time was 69.2 months. Data analysis was performed from December 15, 2022, to March 20, 2023. Patients with GIST at low risk according to Armed Forces Institute of Pathology criteria were included provided adequate clinical information was available: primary site, size, mitotic index, surgical margins, and 2 or more years of follow-up. Exposures: All patients underwent follow-up according to European Society for Medical Oncology (ESMO) guidelines. Main outcomes and measures: The primary outcome was the number of tests needed to identify a relapse according to ESMO guidelines follow-up plan. Secondary outcomes included relapse rate, relapse timing, disease-free survival (DFS), overall survival (OS), GIST-specific survival (GIST-SS), postrelapse OS, secondary tumor rates, and theoretical ionizing radiation exposure. An exploratory end point, new follow-up schedule proposal for patients with low-risk GIST according to the observed results, was also assessed. Results: A total of 737 patients (377 men [51.2%]; median age at diagnosis, 63 [range, 18-86] years) with low-risk GIST were included. Estimated 5-year survival rates were 95.5% for DFS, 99.8% for GIST-SS, and 96.1% for OS. Estimated 10-year survival rates were 93.4% for DFS, 98.1% for GIST-SS, and 91.0% for OS. Forty-two patients (5.7%) experienced disease ...

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/37930700; volume:6; issue:11; numberofpages:14; journal:JAMA NETWORK OPEN; https://hdl.handle.net/10447/621176Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85176376666

الإتاحة: https://doi.org/10.1001/jamanetworkopen.2023.41522Test
https://hdl.handle.net/10447/621176Test

المؤلفون: Tagliamento, Marco, Gennari, Alessandra, Lambertini, Matteo, Salazar, Ramon, Harbeck, Nadia, Del Mastro, Lucia, Aguilar-Company, Juan, Bower, Mark, Sharkey, Rachel, Dalla Pria, Alessia, Plaja, Andrea, Jackson, Amanda, Handford, Jasmine, Sita-Lumsden, Ailsa, Martinez-Vila, Clara, Matas, Marta, Miguel Rodriguez, Ana, Vincenzi, Bruno, Tonini, Giuseppe, Bertuzzi, Alexia, Brunet, Joan, Pedrazzoli, Paolo, D'Avanzo, Francesca, Biello, Federica, Sinclair, Alasdair, Lee, Alvin J X, Rossi, Sabrina, Rizzo, Gianpiero, Mirallas, Oriol, Pimentel, Isabel, Iglesias, Maria, Sanchez de Torre, Ana, Guida, Annalisa, Berardi, Rossana, Zambelli, Alberto, Tondini, Carlo, Filetti, Marco, Mazzoni, Francesca, Mukherjee, Uma, Diamantis, Nikolaos, Parisi, Alessandro, Aujayeb, Avinash, Prat, Aleix, Libertini, Michela, Grisanti, Salvatore, Rossi, Maura, Zoratto, Federica, Generali, Daniele, Saura, Cristina, Lyman, Gary H, Kuderer, Nicole M, Pinato, David J, Cortellini, Alessio

المساهمون: Tagliamento, Marco, Gennari, Alessandra, Lambertini, Matteo, Salazar, Ramon, Harbeck, Nadia, Del Mastro, Lucia, Aguilar-Company, Juan, Bower, Mark, Sharkey, Rachel, Dalla Pria, Alessia, Plaja, Andrea, Jackson, Amanda, Handford, Jasmine, Sita-Lumsden, Ailsa, Martinez-Vila, Clara, Matas, Marta, Miguel Rodriguez, Ana, Vincenzi, Bruno, Tonini, Giuseppe, Bertuzzi, Alexia, Brunet, Joan, Pedrazzoli, Paolo, D'Avanzo, Francesca, Biello, Federica, Sinclair, Alasdair, Lee, Alvin J X, Rossi, Sabrina, Rizzo, Gianpiero, Mirallas, Oriol, Pimentel, Isabel, Iglesias, Maria, Sanchez de Torre, Ana, Guida, Annalisa, Berardi, Rossana, Zambelli, Alberto, Tondini, Carlo, Filetti, Marco, Mazzoni, Francesca, Mukherjee, Uma, Diamantis, Nikolao, Parisi, Alessandro, Aujayeb, Avinash, Prat, Aleix, Libertini, Michela, Grisanti, Salvatore, Rossi, Maura, Zoratto, Federica, Generali, Daniele, Saura, Cristina, Lyman, Gary H, Kuderer, Nicole M, Pinato, David J, Cortellini, Alessio

مصطلحات موضوعية: COVID-19 outcome, breast cancer, cancers

الوصف: Purpose: Although representing the majority of newly diagnosed cancers, patients with breast cancer appear less vulnerable to COVID-19 mortality compared with other malignancies. In the absence of patients on active cancer therapy included in vaccination trials, a contemporary real-world evaluation of outcomes during the various pandemic phases, as well as of the impact of vaccination, is needed to better inform clinical practice. Methods: We compared COVID-19 morbidity and mortality among patients with breast cancer across prevaccination (February 27, 2020-November 30, 2020), Alpha-Delta (December 1, 2020-December 14, 2021), and Omicron (December 15, 2021-January 31, 2022) phases using OnCovid registry participants (ClinicalTrials.gov identifier: NCT04393974). Twenty-eight-day case fatality rate (CFR28) and COVID-19 severity were compared in unvaccinated versus double-dosed/boosted patients (vaccinated) with inverse probability of treatment weighting models adjusted for country of origin, age, number of comorbidities, tumor stage, and receipt of systemic anticancer therapy within 1 month of COVID-19 diagnosis. Results: By the data lock of February 4, 2022, the registry counted 613 eligible patients with breast cancer: 60.1% (n = 312) hormone receptor-positive, 25.2% (n = 131) human epidermal growth factor receptor 2-positive, and 14.6% (n = 76) triple-negative. The majority (61%; n = 374) had localized/locally advanced disease. Median age was 62 years (interquartile range, 51-74 years). A total of 193 patients (31.5%) presented ≥ 2 comorbidities and 69% (n = 330) were never smokers. In total, 392 (63.9%), 164 (26.8%), and 57 (9.3%) were diagnosed during the prevaccination, Alpha-Delta, and Omicron phases, respectively. Analysis of CFR28 demonstrates comparable estimates of mortality across the three pandemic phases (13.9%, 12.2%, 5.3%, respectively; P = .182). Nevertheless, a significant improvement in outcome measures of COVID-19 severity across the three pandemic time periods was observed. Importantly, when ...

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36720089; info:eu-repo/semantics/altIdentifier/wos/WOS:001005235300001; journal:JOURNAL OF CLINICAL ONCOLOGY; https://hdl.handle.net/11573/1667424Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85152187559

الإتاحة: https://doi.org/10.1200/JCO.22.01667Test
https://hdl.handle.net/11573/1667424Test

المؤلفون: Perroni, Gianluca, Radovanovic, Dejan, Mondoni, Michele, Mangiameli, Giuseppe, Giudici, Veronica Maria, Crepaldi, Alessandro, Giatti, Valentina, Morenghi, Emanuela, Stella, Giulia Maria, Pavesi, Stefano, Mantero, Marco, Corsico, Angelo Guido, Spotti, Maura, Premuda, Chiara, Mangilli, Stefano Attilio, Franceschi, Elisa, Narvena, Veronica Macioce, Vanoni, Nicolò, Pilocane, Tommaso, Russo, Gianluca, Di Marco, Fabiano, Alloisio, Marco, Aliberti, Stefano, Marulli, Giuseppe, Bertuzzi, Alexia Francesca, Cipolla, Giuseppe, Centanni, Stefano, Blasi, Francesco, Santus, Pierachille, Cariboni, Umberto

المساهمون: G. Perroni, D. Radovanovic, M. Mondoni, G. Mangiameli, V.M. Giudici, A. Crepaldi, V. Giatti, E. Morenghi, G.M. Stella, S. Pavesi, M. Mantero, A.G. Corsico, M. Spotti, C. Premuda, S.A. Mangilli, E. Franceschi, V.M. Narvena, N. Vanoni, T. Pilocane, G. Russo, F. Di Marco, M. Alloisio, S. Aliberti, G. Marulli, A.F. Bertuzzi, G. Cipolla, S. Centanni, F. Blasi, P. Santu, U. Cariboni

مصطلحات موضوعية: COVID-related tracheal stenosi, SARS-CoV-2 pandemic, tracheal stenosi, tracheostomy, Settore MED/10 - Malattie dell'Apparato Respiratorio

الوصف: Background: Tracheal stenosis represents a fearsome complication that substantially impairs quality of life. The recent SARS-CoV-2 pandemic increased the number of patients requiring invasive ventilation through prolonged intubation or tracheostomy, increasing the risk of tracheal stenosis. Study design and methods: In this prospective, observational, multicenter study performed in Lombardy (Italy), we have exanimated 281 patients who underwent prolonged intubation (more than 7 days) or tracheostomy for severe COVID-19. Patients underwent CT scan and spirometry 2 months after hospital discharge and a subsequent clinical follow-up after an additional 6 months (overall 8 months of follow-up duration) to detect any tracheal lumen reduction above 1%. The last follow-up evaluation was completed on 31 August 2022. Results: In the study period, 24 patients (8.5%, CI 5.6–12.4) developed tracheal stenosis in a median time of 112 days and within a period of 200 days from intubation. Compared to patients without tracheal stenosis, tracheostomy was performed more frequently in patients that developed stenosis (75% vs 54%, p = 0.034). Tracheostomy and alcohol consumption (1 unit of alcohol per day) increased risk of developing tracheal stenosis of 2.6-fold (p = 0.047; IC 0.99–6.8) and 5.4-fold (p = 0.002; CI 1.9–16), respectively. Conclusions: In a large cohort of patients, the incidence of tracheal stenosis increased during pandemic, probably related to the increased use of prolonged intubation. Patients with histories of prolonged intubation should be monitored for at least 200 days from invasive ventilation in order to detect tracheal stenosis at early stage. Alcohol use and tracheostomy are risk factors for developing tracheal stenosis.

العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:001151257200001; volume:14; issue:1; firstpage:1; lastpage:11; numberofpages:11; journal:JOURNAL OF PERSONALIZED MEDICINE; https://hdl.handle.net/2434/1022691Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85183191180

الإتاحة: https://doi.org/10.3390/jpm14010039Test
https://hdl.handle.net/2434/1022691Test

المؤلفون: Bertuzzi, Alexia Francesca, Grimaudo, Maria Susanna, Laffi, Alice, Giordano, Laura, Gennaro, Nicolò, Cariboni, Umberto, Siracusano, Licia Vanessa, Quagliuolo, Vittorio, Colombo, Piergiuseppe, Federico, D’Orazio, Renne, Salvatore Lorenzo, Specchia, Cristina, Cananzi, Ferdinando, Marrari, Andrea, Navarria, Pierina, Daolio, Primo Andrea, Bastoni, Stefano, Santoro, Armando

المصدر: Cancer Medicine ; volume 12, issue 15, page 16254-16263 ; ISSN 2045-7634 2045-7634

الوصف: Introduction The aim of this retrospective study was to investigate the clinicopathological characteristics of AYA sarcomas and their clinical outcomes at a high‐volume single center. Methods Demographic, clinicopathological data on the diagnosis, treatment and follow‐up of all sarcoma patients aged 16–39 years (ys) observed at our Institute between January 2010 and December 2021 were retrospectively collected, including diagnostic (TTD) and treatment delay(TTT), clinical outcomes (OS and PFS), and late‐treatment effects. Results We identified 228 AYA patients, median age 30 years, 29% ≤ 25 years, 57% males, 88% soft tissue sarcomas (STS), and 12% bone sarcomas (BS). Among STSs, 13% were small round cell tumors (SRCT), 52% intermediate–high‐grade, 24% low‐grade STSs. Among BS, 32% were high‐grade. Median TTD and TTT were 120 (0–8255) and 7 days (0–83), respectively. Surgery was performed in 83%, radiotherapy in 29%, and systemic therapy in 27%. Median follow‐up was 72.9 months(1.6–145), 5‐year and 10‐year OS were 78.5% and 62%, respectively. Kaplan–Meyer analysis showed a significantly better 5‐year OS and PFS for patients with >92 days of TTD (OS 85.7% vs. 66.7%, p = 0.001, PFS 50.2% vs. 24.9%, p = 0.009). According to age (≤25 years vs. > 25 years), 5‐year OS was 69.8% versus 82.2%, respectively ( p = 0.047). Conclusion Our analysis confirmed previous data on sarcoma AYA patients followed in a referral center. Unexpectedly, diagnostic delay was not associated with poor OS and PFS. Patients <25 years showed a poorer prognosis due to the higher incidence of SRCT.

الإتاحة: https://doi.org/10.1002/cam4.6289Test

المؤلفون: Grimaudo, Maria Susanna, Laffi, Alice, Gennaro, Nicolò, Fazio, Roberta, D’Orazio, Federico, Samà, Laura, Siracusano, Licia Vanessa, Sicoli, Federico, Renne, Salvatore Lorenzo, Santoro, Armando, Bertuzzi, Alexia Francesca

المصدر: Frontiers in Oncology ; volume 13 ; ISSN 2234-943X

مصطلحات موضوعية: Cancer Research, Oncology

الوصف: Introduction Regorafenib is a tyrosine kinase inhibitor (TKI) approved in metastatic gastrointestinal stromal tumor (GIST), colorectal cancer, and hepatocarcinoma. Anyway, the toxicity profile of Regorafenib standard schedule is associated with poor compliance and a high rate of discontinuation. For this reason, there is a growing need for a Regorafenib personalized schedule emerging from the scientific community. Objective The aim of this case series was to describe the experience of our sarcoma referral center with the continuous administration of Regorafenib as an alternative regimen to treat metastatic GIST patients. Methods We retrospectively collected clinical, pathological, and radiological data of patients with metastatic GIST treated with daily personalized Regorafenib at a single tertiary referral center from May 2021 to December 2022. Results We identified three patients fulfilling the inclusion criteria. The average follow-up since the start of Regorafenib was 19.1 months (12–25 months). All three patients had started a standard third-line Regorafenib schedule according to guidelines. The reasons for switching to a continuous schedule were as follows: exacerbation of symptoms during week-off treatment in the first patient, a serious adverse event (AE) in the second patient, and a combination of both conditions in the third. After switching, none of the patients reported severe AEs, and they improved control of tumor-related symptoms. Two of the patients experienced disease progression after 16 months (9 months of which is continuous schedule) and 12 months (8.1 months of which is continuous schedule) of Regorafenib, respectively; the third patient is still receiving continuous Regorafenib at the time of writing, with a progression-free survival of 25 months (14 months after the modified schedule start). Conclusion With a similar efficacy and lower toxicities, a daily, personalized Regorafenib schedule seems to be a promising alternative to the standard regimen for metastatic GIST patients, including ...

الإتاحة: https://doi.org/10.3389/fonc.2023.1190123Test